Security key
67080M103
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX)
CUSIP: 67080M103
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 103,174,603
- Total 13F shares
- 84,776,704
- Share change
- -3,558,941
- Total reported value
- $783,330,709
- Put/Call ratio
- 11%
- Price per share
- $9.24
- Number of holders
- 171
- Value change
- -$36,480,592
- Number of buys
- 82
- Number of sells
- 83
Report period
Q3 2025
Institutions
171
Top holders
10
NRIX full security history
Newer quarter: Q4 2025
Previous quarter: Q2 2025
Nurix Therapeutics, Inc. SEC filings
Nurix Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 67080M103
Recent filing periods:
Top shareholders of NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
|
Company |
8.2%
from 13D/G
|
6,808,698
|
$77,551,070 | — | 30 Jun 2025 | |
| Commodore Capital LP |
13F
13D/G
|
Company |
4.9%
from 13D/G
|
3,948,653
|
$44,975,158 | — | 30 Jun 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
13F
|
Company |
4.2%
|
3,188,742
|
$36,861,858 | $0 | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
10%
|
10,442,467
|
$118,939,701 | — | 30 Jun 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
5.9%
|
6,064,910
|
$69,079,325 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.3%
|
4,465,507
|
$50,862,125 | — | 30 Jun 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
3.8%
|
3,882,125
|
$44,217,404 | — | 30 Jun 2025 | |
| Redmile Group, LLC |
13F
|
Company |
3.6%
|
3,732,888
|
$42,517,594 | — | 30 Jun 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
3.6%
|
3,703,594
|
$42,183,937 | — | 30 Jun 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2.9%
|
3,033,844
|
$34,556,000 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.5%
|
2,532,154
|
$28,841,234 | — | 30 Jun 2025 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
2.4%
|
2,473,956
|
$28,179,000 | — | 30 Jun 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
2.3%
|
2,422,833
|
$27,596,068 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
2.1%
|
2,167,121
|
$24,683,523 | — | 30 Jun 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.9%
|
2,000,000
|
$22,780,000 | — | 30 Jun 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.9%
|
1,998,634
|
$22,764,441 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.8%
|
1,881,960
|
$21,436,949 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
1.5%
|
1,589,040
|
$18,099,166 | — | 30 Jun 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.5%
|
1,589,035
|
$18,099,109 | — | 30 Jun 2025 | |
| ARK Investment Management LLC |
13F
|
Company |
1.5%
|
1,575,032
|
$17,939,611 | — | 30 Jun 2025 | |
| Sumitomo Mitsui Trust Group, Inc. |
13F
|
Company |
1.3%
|
1,391,638
|
$15,850,757 | — | 30 Jun 2025 | |
| Amova Asset Management Americas, Inc. |
13F
|
Company |
1.3%
|
1,389,274
|
$15,796,045 | — | 30 Jun 2025 | |
| Kynam Capital Management, LP |
13F
|
Company |
1.1%
|
1,173,605
|
$13,367,361 | — | 30 Jun 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
1.1%
|
1,096,985
|
$12,494,659 | — | 30 Jun 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.94%
|
967,620
|
$11,021,192 | — | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.9%
|
927,558
|
$10,564,886 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.63%
|
653,533
|
$7,443,740 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.59%
|
607,127
|
$6,915,177 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.57%
|
584,519
|
$6,657,671 | — | 30 Jun 2025 | |
| Artisan Partners Limited Partnership |
13F
|
Company |
0.56%
|
580,749
|
$6,614,731 | — | 30 Jun 2025 | |
| WASATCH ADVISORS LP |
13F
|
Company |
0.47%
|
486,936
|
$5,546,201 | — | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.41%
|
427,071
|
$4,865,666 | — | 30 Jun 2025 | |
| Patient Square Capital LP |
13F
|
Company |
0.4%
|
412,296
|
$4,696,051 | — | 30 Jun 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.36%
|
374,850
|
$4,269,542 | — | 30 Jun 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.36%
|
368,878
|
$4,201,520 | — | 30 Jun 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.35%
|
356,742
|
$4,063,291 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.32%
|
327,211
|
$3,726,933 | — | 30 Jun 2025 | |
| ArrowMark Colorado Holdings LLC |
13F
|
Company |
0.31%
|
314,762
|
$3,585,139 | — | 30 Jun 2025 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
0.3%
|
310,000
|
$3,530,900 | — | 30 Jun 2025 | |
| BESSEMER GROUP INC |
13F
|
Company |
0.3%
|
306,003
|
$3,485,000 | — | 30 Jun 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.28%
|
284,600
|
$3,241,594 | — | 30 Jun 2025 | |
| Handelsbanken Fonder AB |
13F
|
Company |
0.27%
|
280,000
|
$3,189,000 | — | 30 Jun 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.25%
|
262,384
|
$2,988,681 | — | 30 Jun 2025 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.25%
|
257,816
|
$2,936,524 | — | 30 Jun 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.25%
|
254,870
|
$2,902,969 | — | 30 Jun 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.22%
|
232,055
|
$2,643,106 | — | 30 Jun 2025 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.22%
|
230,828
|
$2,629,131 | — | 30 Jun 2025 | |
| WestHill Financial Advisors, Inc. |
13F
|
Company |
0.22%
|
228,333
|
$2,600,713 | — | 30 Jun 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.22%
|
228,271
|
$2,600,007 | — | 30 Jun 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.22%
|
224,125
|
$2,552,781 | — | 30 Jun 2025 |
Institutional Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) as of Q3 2025
As of 30 Sep 2025,
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) was held by
171 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
84,776,704 shares.
The largest 10 holders included
FMR LLC, BlackRock, Inc., Deep Track Capital, LP, VANGUARD GROUP INC, BAKER BROS. ADVISORS LP, Commodore Capital LP, Redmile Group, LLC, Vestal Point Capital, LP, Point72 Asset Management, L.P., and STATE STREET CORP.
This page lists
171
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
161
Q3 2025 holders
171
Holder diff
10
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.